Subcutaneous versus intramuscular depot methoxyprogesterone acetate: A comparative review

Women's Health

Volumn 2, Issue 2, 2006, Pages 191-197

  Simon, Melissa A ^a   Shulman, Lee P ^a  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

Contraception; Family planning; Subcutaneous injection; Subcutaneous medroxyprogesterone acetate; Women's health

Indexed keywords

AMINOGLUTETHIMIDE; CORTICOSTEROID; LEUPRORELIN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT;

ACNE; ADULT; AMENORRHEA; ANALGESIA; ANXIETY; BLEEDING; BLOATING; BODY WEIGHT DISORDER; BONE DENSITY; BONE DISEASE; BREAKTHROUGH BLEEDING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTRACEPTION; DEPRESSION; DISEASE EXACERBATION; DISORDERS OF CARBOHYDRATE METABOLISM; DISORDERS OF LIPOPROTEIN METABOLISM; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DYSPAREUNIA; ENDOMETRIAL DISEASE; ENDOMETRIOSIS; ENDOMETRIUM ATROPHY; ENDOMETRIUM CANCER; FEMALE; FRAGILITY FRACTURE; HAIR LOSS; HIRSUTISM; HOT FLUSH; HUMAN; INTERMETHOD COMPARISON; LIBIDO DISORDER; LOW DRUG DOSE; MASTALGIA; MENSTRUAL IRREGULARITY; MOOD CHANGE; OSTEOPENIA; OVARY CANCER; PAIN; PLASMA PROTEIN BINDING; REVIEW; SPOTTING; UNITED STATES; VASOMOTOR DISORDER; WEIGHT GAIN;

EID: 33646784757     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.2.2.191     Document Type: Review

References (33)

1. Kaunitz AM: Injectable contraception. New and existing options. Obstet. Gynecol. Clin. North Am. 27, 741-780 (2000).
2. Pfizer data on file: Kalamzoo (MI): Pharmacia & Upjohn Company, a subsidiary of Pharmacia Corporation. 12-6-2002 NY, USA (2004).
3. Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM: Contraceptive efficacy and safety of DMPA-SC. Contraception 70, 269-275 (2004).
4. Kaunitz AM: Long-acting injectable contraception with depot medroxyprogesterone acetate. Am. J. Obstet. Gynecol. 170, 1543-1549 (1994).
5. Petta CA, Faundes A, Dunson TR et al.: Timing of onset of contraceptive effectiveness in Depo-Provera users: part I changes in cervical mucus. Fertil. Steril. 69, 252-257 (1998).
6. Jain J, Dutton C, Nicosia A et al.: Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera. Contraception 70(1), 11-18 (2004).
7. Toh YC, Jain J, Rahnny MH et al.: Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104mg/0.65ml) contraceptive formulation in asian women. Clin. Ther. 26(11), 1845-1854 (2004).
8. Depo SubQ Provera 104™, package insert. Pfizer, MA, USA (2005).
9. Mishell DR: Pharmacokinetics of depot medroxyprogesterone acetate contraception. J. Reprod. Med. 41, 381-390 (1996).
10. Trussell J: Contraceptive efficacy. In: Contraceptive Technology. Hatcher RA, Trussell J, Stewart F et al. (Eds). Ardent Media Inc., NY, USA, 779-845 (1998).
11. Lakha F, Henderson C, Glasier A: The acceptability of self-administration of subcutaneous Depo-Provera. Contraception 72(1), 14-18 (2005).
12. De Abood M, de Castillo, Guerrero E et al.: Effect of Depo-Provera or Microgynon in the painful crises of sickle-cell anemia patients. Contraception 56, 313-316 (1997).
13. Zhou J, Lei ZW, Lu JQ et al.: Conservative surgery combined with depot medroxyprogesterone acetate in treatment of moderate or severe endometriosis. Zho-ghua Fu Chan Ke Za Zhi 40(1), 5-8 (2005).
14. Crosignani PG, Luciano A, Ray A, Bergqvist A: Subcutaneous depo medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum. Reprod. 21(1), 248-256 (2006).
15. Winkel CA: Evaluation and management of women with endometriosis. Obstet. Gynecol. 102, 397-408 (2003).
16. Depo-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer: The WHO Collaborative Study of Neoptasia and Steroid Contraceptives. Int. J. Cancer 49, 186-190 (1991).
17. Holt VL, Cushing-Haugen KL, Dating JR: Body weight and risk of oral contraceptive failure. Obstet. Gynecol. 99, 820-827 (2002).
18. Zieman M, Guillebaud J, Weisberg E et al: Contraceptive efficacy and cyle control with the Ortho Evra transdermal system: the analysis of pooled data. Fertil. Steril. 77, S13-S18 (2002).
19. Belsey EM: Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception. Contraception 38, 181-206 (1988).
20. Mainwaring R, Hales HA, Stevenson KE et al.: Metabolic parameter, bleeding and weight changes in US women using progestin-only contraceptives. Contraception 51, 149-153 (1995).
21. Westhoff C, Wieland D, Tiezzi L: Depression in users of depo-medroxyprogesterone acetate. Contraception 51, 351-354 (1995).
22. Orr-Walker BJ, Evans MC, Ames RW et al.: The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin. Endocrinol. (Oxf) 49(5), 615-618 (1998).
23. Cundy T, Evans M, Roberts H et al.: Bone density in women receiving depot medroxyprogesterone acetate for contraception. Br. Med. J. 303, 13-16 (1991).
24. Banks E. Berrington A, Casabonne D: Overview of the relationship between use of progestogen-only contraceptives and bone mineral density. Br. J. Obstet. Gynaecol. 108, 1214-1221 (2001).
25. Tang OS, Tang G, Yip PS et al.: Further evaluation on long-term depot medroxyprogesterone acetate use and bone mineral density: a longitudal cohort study. Contraception 62, 161-164 (2000).
26. Petitti DB, Piaggio G, Mehta S et al.: Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. Obstet. Gynecol. 95, 736-744 (2000).
27. Scholes D, LaCroix AZ, Ischikawa LE et al.: Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch. Pediatr. Adolesc. Med. 159, 139-144 (2005).
28. World Health Organization statement on hormonal contraception and bone health: Weekly Epidemiological Record. No 35, 2 September, 80, 302-304. World Health Organization, Geneva, Switzerland (2005).
29. Kaunitz AM: Depo-Provera's black box: time to reconsider? Contraception 72, 165-167 (2005).
30. Cardiovascular disease and use of oral and injectable progestin-only contraceptives and combined injectable contraceptives: results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 57, 315 (1998).
31. Canto De Cetina TE, Canto P, Luna MO: Effect of counseling to improve compliance in Mexican women receiving depo-medroxyprogesterone acetate. Contraception 63, 143-146 (2001).
32. Lei ZW, Wu SC, Garceau RJ et al.: Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception. Contraception 53, 357-361 (1996).
33. Centers for Disease Control: Achievements in public health, 1990-1999: family planning. MMWR Morb. Mortal. Wkly Rep. 48, 1073-1080 (1999).